Switching on kinases: Oncogenic activation of BRAF and the PDGFR family

Nature Reviews Cancer

Volumn 4, Issue 9, 2004, Pages 718-727

  Dibb, Nick J ^a   Dilworth, Stephen M ^a   Mol, Clifford D ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Takeda San Diego Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BCR ABL PROTEIN; FLT3 LIGAND; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN SERINE THREONINE KINASE; STEM CELL FACTOR; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; ENZYME INHIBITOR; PHOSPHOTRANSFERASE; RAF PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; AUTOPHOSPHORYLATION; BLAST CELL CRISIS; CARCINOGENESIS; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE ACTIVATION; GENE ACTIVITY; GENE MUTATION; GENE STRUCTURE; HUMAN; LEUKEMIA REMISSION; MULTIGENE FAMILY; MUTATIONAL ANALYSIS; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY; BIOSYNTHESIS; CELL TRANSFORMATION; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; MOLECULAR GENETICS; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY;

AMINO ACID SEQUENCE; BASE SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; ONCOGENES; PHOSPHOTRANSFERASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 4544302751     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1434     Document Type: Review

References (85)

1. Pollock, P. M. & Meltzer, P. S. Lucky draw in the gene raffle Nature 417, 906-907 (2002).
2. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
3. Mercer, K. E. & Pritchard, C. A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta 1653, 25-50 (2003).
4. Yang, S. H., Sharrocks, A. D. & Whitmarsh, A. J. Transcriptional regulation by the MAP kinase signalling cascades. Gene 320, 3-21 (2003).
5. Pollock P. M. et al. High frequency of BRAF mutations in nevi. Nature Genet. 33, 595-602 (2003).
6. Wan, P. T. C. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
7. Furitsu, T. et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukaemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92, 1736-1744 (1993).
8. Glover, H. R., Baker, D. A., Celetti, A. & Dibb, N. J. Selection of activating mutations of c-fms in FDC-P1 cells. Oncogene 11, 1347-1356 (1995).
9. Yeung, Y.-G. & Stanley, E. R. Proteomic approaches to the analysis of early events in colony-stimulating factor-1 signal transduction. Mol. Cell. Proteomics 2, 1143-1155.
10. Lev, S., Blechman, J. M., Givol, D. & Yarden, Y. Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit. Rev. Oncog. 5, 141-168 (1994).
11. Heldin, C. H. & Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79, 1283-1316 (1999).
12. Stirewalt, D. L. & Radich, J. P. The role of FLT3 in haematopoietic malignancies. Nature Rev. Cancer 3, 650-665 (2003).
13. Ullrich, A. & Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 61, 203-212 (1990).
14. Kacinski, B. M. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol. Reprod. Dev. 46, 71-74 (1997).
15. Nagata, H. et al. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl Acad. Sci USA 92, 10560-10564 (1995).
16. Reilly J. T. Class III receptor tyrosine kinases: role in leukaemogenesis. Br. J. Haematol. 116, 744-757 (2002).
17. Hirota, S. et al. Gain of function mutations of c-kit in human gastrointestinal stromal tumours. Science 279, 577-580 (1998).
18. Kemmer, K. et al. KIT mutations are common in testicular seminomas. Am. J. Pathol. 164, 305-313 (2004).
19. Hirota, S. et al. Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumours. Gastroenterology 125, 660-667 (2003).
20. Heinrich, M. C. et al. PDGFRA activating mutations in gastrointestinal stromal tumours. Science 299, 708-710 (2003).
21. Kitayama, H. et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85, 790-798 (1995).
22. Johnson, L. N., Noble, M. E. M. & Owen, D. J. Active and inactive protein kinases: structural basis for regulation. Cell 85, 149-158 (1996).
23. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
24. Huse, M. & Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275-282 (2002).
25. Knighton, D. R., et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 407-414 (1991).
26. Hubbard, S. R., Ellis, L. & Hendrickson, W. A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 748-754 (1994).
27. Hubbard, S. R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16, 5573-5581 (1997).
28. Pautsch, A. et al. Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into domain movements upon kinase activation. Structure 9, 955-965 (2001).
29. Munshi, S. et al. Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. J. Biol. Chem. 277, 38797-38802 (2001).
30. Mol, C. D. et al. Structure of a c-Kit product complex reveals the basis for kinase transactivation. J. Biol. Chem. 278, 31461-31464 (2003).
31. Mol, C. D. et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 279, 31655-31663.
32. Yamaguchi, H. & Hendrickson W. A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 348, 484-489 (1996).
33. Schindler, T. et al. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3, 639-648 (1999).
34. Yang, J. et al. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nature Struct. Biol. 9, 940-944 (2002).
35. Yang, J. et al. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol. Cell 9, 1227-1240 (2002).
36. Wang, Z., Harkins, P. C., Ulevitch, R. J., Cobb, M. H. & Goldsmith, E. J. The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. Proc. Natl Acad. Sci. USA 94, 2327-2332 (1997).
37. Bellon, S., Fitzgibbon, M. J., Fox, T. & Hsiao, H. M. & Wilson K. P. The structure of phosphorylated p38γ is monomeric and reveals a conserved activation-loop conformation. Structure Fold Des. 7, 1057-1065 (1999).
38. Canagarajah, B. J., Khokhlatchev, A., Cobb, M. H. & Goldsmith, E. J. Activation mechanism of the MAP Kinase ERK2 by dual phosphorylation. Cell 90, 859-869 (1997).
39. Engh, R. A. & Bossenmeyer, D. Structural aspects of protein kinase control - role of conformational flexibility. Pharmacol. Ther. 93, 99-111 (2002).
40. De Bondt, H. et al. Crystal structure of cyclin-dependent kinase 2. Nature 363, 595-602 (1993).
41. Jeffrey, P. D. et al. Mechanism of CDK activation revealed by the structure of a cyclin-A CDK2 complex. Nature 376, 313-320 (1995).
42. Lowe, E. D. et al. Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. Biochemistry 41, 15625-15634 (2002).
43. Malumbres, M. & Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nature Rev. Cancer 1, 222-231 (2001).
44. Russo, A. A., Jeffrey, P. D. & Pavletich, N. P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nature Struct. Biol. 3, 696-700 (1996).
45. Stamos, J., Sliwkowski, M. X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265-46272 (2002).
46. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B. & Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942 (2000).
47. Bohmer, F. D. et al. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J. Biol. Chem. 278, 5148-5155 (2003).
48. Zhang, B. H. & Guan K. L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 19, 5429-5439 (2000).
49. Chan, P. M., Ilangumaran, S., La Rose, J., Chakrabartty, A. & Rottapel, R. Autoinhibition of the Kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol. Cell. Biol. 23, 3067-3078 (2003).
50. Wybenga-Groot, L. et al Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106, 745-757 (2001).
51. Li, S., Covino, N. D., Stein, E. G., Till, J. H. & Hubbard, S. R. Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor. J. Biol. Chem. 278, 26007-26014 (2003).
52. Huse, M., Chen, Y.-G., Massague, J. & Kuriyan, J. Crystal structure of the cytoplasmic domain of the type I TGFβ receptor in complex with FKBP12. Cell 96, 425-436 (1999).
53. Griffith, J. et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 13, 169-178 (2004).
54. Morley, G. M., Uden, M., Gullick, W. J. & Dibb, N. J. Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation. Oncogene 18, 3076-3084 (1999).
55. Ma, Y. et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99, 1741-1744 (2002).
56. Longley, B. J., Reguera, M. J. & Ma, Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk. Res. 25, 571-576 (2001).
57. Zermati, Y. et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasm. Oncogene 22, 660-664 (2003).
58. Moriyama, Y. et al. Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase. J. Biol. Chem. 271, 3347-3350 (1996).
59. Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100-104 (1996).
60. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N. Engl. J. Med. 344, 1031-1037 (2001).
61. Joensuu, H. et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 3, 655-664 (2002).
62. Skorski, T. Oncogenic tyrosine kinases and the DNA-damage response. Nature Rev. Cancer 2, 351-360 (2002).
63. Buchdunger, E. et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139-145 (2000).
64. Apperley, J. F. et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N. Engl. J. Med. 347, 481-487 (2002).
65. Pietras, K., Sjoblom, T., Rubin, K., Heldin, C.-H. & Ostman, A. PDGF receptors as cancer drug targets. Cancer Cell 3, 439-443 (2003).
66. Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukaemia. Cancer Cell 2, 117-125 (2002).
67. Gambacorti-Passerini, C. B. et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 4, 75-85 (2003).
68. Harrison, S. C. Variation on an Src-like theme. Cell 112, 737-740 (2003).
69. Azam, M., Latek, R. R. & Daley, G. Q. Mechanisms of autoinhibition and STI-571/Imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831-843 (2003).
70. Papa, F. R., Zhang, C., Shokat, K. & Walter P. Bypassing a kinase activity with an ATP-competitive drug. Science 302, 1533-1537 (2003).
71. Hubbard, S. R. Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr. Opin. Struct. Biol. 12, 735-741 (2002).
72. Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859-871 (2003).
73. Sawyers, C. L. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukaemia. Cancer Cell 1, 413-415 (2002).
74. Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony stimulating factor 1 promotes progression of mammary tumours to malignancy. J. Exp Med. 193, 727-740 (2001).
75. Murray, L. J. et al. SU11248 inhibits tumor growth and CSF-1R dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Mestastasis 20, 757-766 (2003).
76. Bardelli, A. et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300, 949 (2003).
77. Robertson, S. C., Tynan, J. A. & Donoghue, D. J. RTK mutations and human syndromes: when good receptors turn bad. Trends Genet. 16, 265-271 (2000).
78. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004)
79. Paez, J. G. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
80. Eisenberg, D. The discovery of the α-helix and β-sheet, the principal structural features of proteins. Proc. Natl Acad. Sci. USA 100, 11207-11210 (2003).
81. Ma, Y. et al. Inhibition of spontaneous receptor phosphorylation by residues in a putative α-helix in the KIT intracellular region. J. Biol. Chem. 274, 13399-13402 (1999).
82. Antonescu, C. R. et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behaviour: KIT analysis and clinical correlates of 120 gastrointestinal stromal tumours. Clin. Cancer Res. 9, 3329-3337 (2003).
83. Lasota, J., Jasinski, M., Sarlomo-Rikala, M. & Miettinen, M. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumours and do not occur in leiomyomas or leiomyosarcomas. Am. J. Pathol. 154, 53-60 (1999).
84. Hou, Y. Y. et al. C-kit gene mutation in human gastrointestinal stromal tumours. World J. Gastroenterol. 10, 1310-1324 (2004).
85. Rubin, B. P. et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61, 8118-8121 (2001).